Prevalence of liver fibrosis determined by non-invasive methods in patients with metabolic disorders at the Centro Medico Nacional 20 de noviembre

Abstract

Introduction and Objective: This study aimed to determine the prevalence of liver fibrosis through non-invasive methods in patients with metabolic disorders. Materials and Methods: Observational, cross-sectional, and retrospective analytical study. Laboratory results and images of patients diagnosed with metabolic alterations in the CMN 20 de Noviembre will be collected. Results: Among the results obtained, we found that the prevalence of fibrosis was 18.1%, and hepatic steatosis was 59.8%. Discussion: ALT, C-peptide, and insulin levels were significantly higher in the group with fibrosis. When the variables were dichotomized, an OR of 2.91 (95% CI 1.099 – 7.73) was found for ALT >38.5; Insulin > 17.75, the OR was 3.199 (95% CI 1.20 – 8.5); and for C-peptide > 945 OR 4.049 (95% CI 1.42 – 11.51). The albumin level was significantly lower in this group p = 0.041, with an OR 0.29 (95% CI 0.104 – 0.815), so a value greater than 4.35 represents a protective factor. The NALFD score and FIB4 showed a weak positive correlation with the measurements made with the Fibroscan®. Conclusions: The determination of liver fibrosis did not correlate through the different non-invasive methods, so it would be best to establish non-invasive liver-specific markers in patients with metabolic disorders and steatohepatitis for the diagnosis of liver fibrosis; since the necessary and accurate diagnostic tools that meet the criteria of efficacy, accuracy, and reliability are not available. Funding: The resources used in this study were from the hospital without any additional financing Declaration of interest: The authors declare no potential conflicts of interest.